Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch

Author(s): Pooja Ratre, Keerti Mishra, Amit Dubey, Amber Vyas, Akhlesh Jain*, Suresh Thareja*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 20 , Issue 17 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Estrogens are essential for the growth of breast cancer in the case of premenopausal as well as in postmenopausal women. However, most of the breast cancer incidences are reported in postmenopausal women and the concurrent risk surges with an increase in age. Since the enzyme aromatase catalyses essential steps in estrogen biosynthesis, Aromatase Inhibitors (AIs) are effective targeted therapy in patients with Estrogen Receptor positive (ER+) breast cancer. AIs are more effective than Selective Estrogen Receptor Modulators (SERMs) because they block both the genomic and nongenomic activities of ER. Till date, first, second and third-generation AIs have been approved by the FDA. The third-generation AIs, viz. Letrozole, Anastrozole, Exemestane, are currently used in the standard treatment for postmenopausal breast cancer.

Methods: Data were collected from Medline, PubMed, Google Scholar, Science Direct through searching of keywords: ‘aromatase’, ‘aromatase inhibitors’, ‘breast cancer’, ‘steroidal aromatase inhibitors’, ‘non-steroidal inhibitors’ and ‘generations of aromatase inhibitors’.

Results: In the current scenario of breast cancer chemotherapy, AIs are the most widely used agents which reveal optimum efficacy along with the least side effects. Keeping in view the prominence of AIs in breast cancer therapy, this review covered the detailed description of aromatase including its role in the biosynthesis of estrogen, biochemistry, gene expression, 3D-structure, and information of reported AIs along with their role in breast cancer treatment.

Conclusion: AIs are the mainstream solution of the ER+ breast cancer treatment regimen with the continuous improvement of human understanding of the importance of a healthy life of women suffering from breast cancer.

Keywords: Aromatase, breast cancer, estrogen biosynthesis, aromatase inhibitors, steroidal aromatase inhibitors, non-steroidal aromatase inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 17
Year: 2020
Published on: 12 November, 2020
Page: [1994 - 2004]
Pages: 11
DOI: 10.2174/1871520620666200627204105
Price: $65

Article Metrics

PDF: 21